ArticleAsian Pacific journal of cancer prevention : APJCP2022
3D-CRT versus RapidArc in Deep Tempero-Parietal High Grade Gliomas: Do We Really Need Higher Technology?
Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to dosimetrically compare single arc RapidArc with conventional 3D-CRT plans for tempero-parietal high grade gliomas with respect to PTV coverage and doses perceived by surrounding critical organs at risk.
methodsThirty patients with the pathological diagnosis of high grade gliomas (WHO grade III-IV) were selected to be enrolled in our study. Patients were referred to our center (center of Clinical Oncology and Radiotherapy, Cairo University) during the period March 2020 till June 2021 for post-operative irradiation using 3D-CRT technique. For all patients, the dose prescribed to the planning target volume (PTV) was 60 Gy in 30 fractions. A RA plan was performed for each patient and dosimetrically was compared to the 3D-CRT plan.
resultsThe PTV coverage in terms of V95% was significantly superior in the RA plans with values of 98.4 ± 1.7 compared to 94.4 ± 2.6 for the 3D-CRT plans (p-value of 0.004). The doses risk structures ( eyes, optic nerves and cochleae) was lower with the RA plans as contrasted to the 3D-CRT plan with an exception for the intraocular lens which received higher doses in the RA plan with a statistically significant p-value of 0.001 and 0.002 for the Ipsilateral and contralateral lens, respectively. The average number of MUs ± SD was 358.6± 44.4 for the RA plans versus 247.6 ± 16.1 for 3D-CRT plans (p-value 0.001). The Dmean of healthy brain tissue was nearly equal for both plans (p-value of 0.071).
conclusionThe plans achieved by RA showed superior dose conformity, PTV coverage, more homogeneous dose distribution when contrasted to 3D-CRT plans. With the exception of both intraocular lenses, the RA plans showed better OAR sparing and utilized a higher number of MUs compared to the 3D-CRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.